Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD JakaviⓇ - Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03491215 REACH4 (CINC424F12201) Acute graft versus host disease Phase 2 45 Measurement of PK parameters Overall Response Rate (ORR) Ruxolitinib NCT03774082 REACH5 (CINC424G12201) Chronic graft versus host disease Phase 2 42 Overall Response Rate (ORR) Ruxolitinib 5mg tablets / pediatric formulation Pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem cell transplantation Pediatric subjects with moderate and severe chronic Graft vs. Host disease after allogeneic stem cell transplantation Target Patients Read-out Milesstone(s) 2023 Publication TBD 120 Investor Relations | Q3 2021 Results 2023 TBD NOVARTIS | Reimagining Medicine

View entire presentation